Investing.com - HCW Biologics reported on Monday third quarter earnings that beat analysts' forecasts and revenue that topped expectations.
HCW Biologics announced earnings per share of $-0.14 on revenue of $1.8M. Analysts polled by Investing.com anticipated EPS of $-0.16 on revenue of $0.00.
HCW Biologics shares are up 100% from the beginning of the year, still down 34.67% from its 52 week high of $3.49 set on November 8, 2021.
HCW Biologics follows other major Healthcare sector earnings this month
HCW Biologics's report follows an earnings beat by UnitedHealth on October 14, who reported EPS of $5.79 on revenue of $80.89B, compared to forecasts EPS of $5.43 on revenue of $80.52B.
J&J had beat expectations on October 18 with third quarter EPS of $2.55 on revenue of $23.79B, compared to forecast for EPS of $2.52 on revenue of $23.46B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar